San Francisco, CA, United States of America

Christina Theodoris

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: The J. David Gladstone Institutes, a Testamentary Trust Established Under the Will of J. David Gladstone, University of California. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Christina Theodoris. Retrieved from https://idiyas.com/inventor/christina-theodoris

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

 

Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Christina Theodoris: Innovator in Cardiac Valve Disease Treatment

Introduction

Christina Theodoris is an accomplished inventor based in San Francisco, CA. She has made significant contributions to the field of cardiac health, particularly in the treatment of cardiac valve disease. Although she currently holds no granted patents, her work is noteworthy and reflects her dedication to medical innovation.

Latest Patent Applications

Christina's latest patent application is titled "Methods for Treating Cardiac Valve Disease." This application provides methods for treating conditions such as calcific aortic valve disease (CAVD) by administering a therapeutically effective amount of specific compounds. Additionally, the application outlines methods for identifying candidate compounds for the treatment of cardiac valve disease.

Conclusion

Christina Theodoris is a promising inventor whose work in cardiac valve disease treatment showcases her commitment to advancing medical science. Her innovative approaches have the potential to significantly impact patient care in the future.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…